利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.018 秒)

    Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
    22.
    发明申请
    Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors 审中-公开

    公开(公告)号：US20140205592A1

    公开(公告)日：2014-07-24

    申请号：US14221370

    申请日：2014-03-21

    申请人： Guenther ADOLF ,  Pilar GARIN-CHESA ,  Ulrich HIRT

    发明人： Guenther ADOLF ,  Pilar GARIN-CHESA ,  Ulrich HIRT

    IPC分类号： G01N33/574 ,  C12Q1/68

    CPC分类号： G01N33/57492 ,  C12Q1/6886 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2800/52

    摘要： The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor. In a further aspect, the present invention relates to a PTK2 inhibitor for use in the treatment of a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2. The present invention also provides a method of screening for a therapeutically effective PTK2 inhibitor comprising the steps of (a) providing cancer cells or a cancer cell line which are characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being even more preferred); (b) contacting the cancer cell or the cancer cell line of (a) with a PTK2 inhibitor; and (c) evaluating whether the PTK2 inhibitor negatively affects the cancer cell/cancer cell lines. In a further aspect, the present invention relates to a method for stratifying cancer patients that are susceptible to treatment with a PTK2 inhibitor, comprising determining the E-cadherin IRS score in a cancer sample of said patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 (i.e. 2, 1, or 0) indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The present invention also relates to a pharmaceutical package comprising a PTK2 inhibitor, and (a) instructions and/or an imprint indicating that said PTK2 inhibitor is to be used for the treatment of patients which suffer from a cancer which is characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being more preferred); and/or (b) instructions and/or an imprint indicating that said patient is to be stratified by a method of the present invention; and/or (c) means to carry out a method as defined herein.

    Method for treating cancers which present antigen FB5 with humanized antibodies
    25.
    发明授权
    Method for treating cancers which present antigen FB5 with humanized antibodies 有权
    用人源化抗体治疗呈现抗原FB5的癌症的方法

    公开(公告)号：US06391302B1

    公开(公告)日：2002-05-21

    申请号：US09633653

    申请日：2000-08-07

    申请人： Thomas Paul Wallace ,  Francis Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    发明人： Thomas Paul Wallace ,  Francis Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    IPC分类号： A61K39395

    CPC分类号： C07K16/30 ,  C07K2317/24 ,  C07K2319/00

    摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

    摘要翻译： 本发明提供了针对抗原FB5特异的几种人源化鼠抗体的产生，其被鼠抗体FB5识别。 FB5抗原在广泛恶性肿瘤的血管内皮细胞的腔表面上表达。 本发明还提供编码人源化FB5特异性抗体的许多多核苷酸，用于产生人源化FB5特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。 本发明还提供使用人源化FB5特异性抗体检测癌细胞（体外和体内）的方法。 另外，本发明提供了使用FB5特异性抗体治疗癌症的方法。

    Method for detecting cancers
    26.
    发明授权
    Method for detecting cancers 有权
    检测癌症的方法

    公开(公告)号：US6124106A

    公开(公告)日：2000-09-26

    申请号：US266119

    申请日：1999-03-10

    申请人： Thomas Paul Wallace ,  William Joseph Harris ,  Francis Joseph Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    发明人： Thomas Paul Wallace ,  William Joseph Harris ,  Francis Joseph Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    IPC分类号： G01N33/574 ,  G01N33/68

    CPC分类号： G01N33/6854 ,  G01N33/57484 ,  G01N33/6833

    摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed in all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.

    摘要翻译： 本发明提供了针对抗原LK26特异的几种人源化鼠抗体的产生，其被鼠抗体LK26识别。 该抗原在所有绒癌，畸胎癌和肾癌细胞系中表达，而在白血病，淋巴瘤，神经外胚层衍生和上皮肿瘤细胞系（除了上皮细胞系的一小部分）的细胞系上不表达。 此外，肾癌细胞株表达LK26抗原时，肾上皮细胞不正常。 类似地，除了滋养层之外，所有正常的成年和胎儿组织检测对于LK26表型是阴性的。 本发明还提供编码人源化LK26特异性抗体的多种多核苷酸，用于产生人源化LK26特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。 本发明还提供了使用人源化LK26特异性抗体检测癌细胞（体外和体内）的方法。 另外，本发明提供使用LK26特异性抗体治疗癌症的方法。